Amygdala Neurosciences Overview
- Founded
- 2015
- Status
- Private
- Latest Deal Type
- Seed
- Latest Deal Amount
- $5.6M
- Investors
- 2
Amygdala Neurosciences General Information
Description
Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated craving without changes to basal dopamine, enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking.
Contact Information
Website
www.amygns.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 5214F Diamond Heights Boulevard
- Suite 151
- San Francisco, CA 94131
- United States
+1 (650) 000-0000
Amygdala Neurosciences Timeline
Amygdala Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Seed Round | 28-Apr-2021 | $5.6M | 000.00 | 000.00 | Completed | Generating Revenue |
| 5. Grant | 21-Oct-2019 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 4. Grant | 19-Sep-2018 | 000.00 | 00.000 | Completed | Generating Revenue | |
| 3. Seed Round | 19-May-2017 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 2. Seed Round | 10-Feb-2017 | $2M | $3.45M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 10-Apr-2015 | $1.45M | $1.45M | 000 | Completed | Generating Revenue |
Amygdala Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-4 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed-3 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Seed-2 | 4,340,673 | $0.000100 | $0.03 | $0.55 | $0.55 | 1x | $0.5 | 11.97% |
| Seed-1 | 5,307,464 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 13.24% |
Amygdala Neurosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use
Drug Discovery
San Francisco, CA
000.00
00.00
0000-00-00
000000000
000.00
00000000
derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
New York, NY
000000000000
0000000
do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Framingham, MA
00
As of 0000
000.00
0000
0000-00-00
00000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAmygdala Neurosciences Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidence Therapeutics | Accelerator/Incubator Backed | New York, NY | 000000000000 | |||
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 000000000000 | Formerly VC-backed | Grand Rapids, MI | 0 | 0000 | 000000&0 | 0000 |
| 0000000 | Formerly VC-backed | Calabasas, CA | 00 | 0000 | 000000&0 | 0000 |
| 0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 00000 00000 |
Amygdala Neurosciences Patents
Amygdala Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3863424-A1 | Addiction treatment of an alcohol-consuming patient population | Pending | 12-Oct-2018 | 0000000000 | |
| US-20210220376-A1 | Addiction treatment of an alcohol-consuming patient population | Pending | 12-Oct-2018 | 0000000000 | |
| US-20210145844-A1 | Combination therapy for nicotine addiction | Pending | 27-Jul-2018 | 0000000000 | |
| EP-3829562-A1 | Combination therapy for nicotine addiction | Pending | 27-Jul-2018 | 0000000000 | |
| EP-3697415-A4 | Combination therapy for preventing addiction | Pending | 16-Oct-2017 | A61K31/4418 | 0 |
Amygdala Neurosciences Executive Team (6)
Amygdala Neurosciences Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Howard Jaffe | Amygdala Neurosciences | Board Member | 000 0000 |
| Ivan Diamond Ph.D | Amygdala Neurosciences | Co-Founder, Board Member & Chief Scientific Officer | 000 0000 |
| Louis Lange MD | Amygdala Neurosciences | Co-Founder & Executive Chairman | 000 0000 |
| Mack Mitchell MD | Self | Chief Medical Officer & Board Member | 000 0000 |
| Peter Strumph | Amygdala Neurosciences | Co-Founder & Board Member | 000 0000 |
Amygdala Neurosciences Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| National Institutes of Health | Government | 000 0000 | 000000 0 |
Amygdala Neurosciences Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 16-Feb-2017 | 000000000 | Buildings and Property | 00000 000 |